A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors
- 15 September 1994
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 58 (6) , 877-881
- https://doi.org/10.1002/ijc.2910580622
Abstract
It was recently found that urokinase-type plasminogen activator (uPA) is involved in the cleavage of its receptor (uPAR) on cultured cells, thereby releasing one of the receptor's 3 domains (the ligand binding domain I) and leaving the 2 others [uPAR(2 + 3)] anchored to the cell surface. With monoclonal antibodies (MAbs) we have now identified human uPAR(2 + 3) in lysates of invasive human MDA-MB-231 mammary carcinomas xenografted into nude mice. The production of peptide antibodies recognizing different domains of murine uPAR made it possible to identify a similar cleaved form of uPAR, murine uPAR(2 + 3), in extracts of primary Lewis lung carcinomas. Cleavage of uPAR also occurs in cultured MDA-MB-231 cells and Lewis lung carcinoma cells. This cleavage is inhibited by anticatalytic antibodies to either human or murine uPA, respectively, indicating that it is catalyzed by either uPA or plasmin generated by uPA. The amount of uPAR(2 + 3) may therefore be directly related to the activity of the uPA system and it is possible that the level of uPAR(2 + 3) in cancer tissue may prove to be a stronger prognostic parameter than the levels of either full-length uPAR or UPA.Keywords
This publication has 21 references indexed in Scilit:
- Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasionInternational Journal of Cancer, 1994
- lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasisEuropean Journal Of Cancer, 1992
- Identification and characterization of the murine cell surface receptor for the urokinase‐type plasminogen activatorEuropean Journal of Biochemistry, 1992
- Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.The Journal of cell biology, 1991
- Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptorFEBS Letters, 1991
- The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.The Journal of cell biology, 1990
- Plasminogen Activators, Tissue Degradation, and CancerPublished by Elsevier ,1985
- A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.The Journal of cell biology, 1985
- Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.The Journal of cell biology, 1984
- Monoclonal antibody that specifically inhibits a human M r 52,000 plasminogen-activating enzymeProceedings of the National Academy of Sciences, 1982